Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
NCT04909515 · Y-mAbs Therapeutics · PHASE2 · withdrawn · last registry update 2022-09-01 · Neuroblastoma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated due to business priorities” | Open Targets' class: business administrative | Registry record, Y-mAbs Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF2RA in neuroblastoma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-03-14Results posted on the registry: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT03786783)
- 2023-02-24Results posted on the registry: St. Jude Children's Research Hospital, cyclophosphamide + topotecan (NCT01857934)
- 2022-11-04Also stopped (terminated): University of Cologne, antibody ch14.18 + GM-CSF (NCT02641782)
- 2022-05-16Results posted on the registry: Memorial Sloan Kettering Cancer Center, anti-GD2 murine IgG3 monoclonal antibody 3F8 + anti-GD2 murine IgG3 monoclonal antibody 3F8 (NCT00072358)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision